Resultado de búsqueda
Hace 6 horas · However, in the placebo arm, only 26% of patients at high cardiovascular risk improved to intermediate risk and 13% improved from intermediate to low cardiovascular risk.
Hace 3 horas · The study is comparing a placebo arm to the intervention, which is a ... $31.1 for G&A, totaling $142.9 million. Of ... Investors are piling in. Intellia has built up a market cap of $2.4 ...
Hace 13 horas · Effet du traitement avec lanifibranor versus placebo sur les marqueurs de santé cardiométabolique à 24 semaines (n=247 patients) Différence moyenne ajustée par rapport au placebo à l’EOT (SE)
Hace 13 horas · The most common adverse reactions (≥ 10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease. ... Market Cap 1.10B. Float 190.88M. Insiders Ownership 1.21%. Institutions Ownership 88.11%. Short Percent 15.65%.
Hace 13 horas · Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG ...
Hace 7 horas · Level the playing field with access to the latest investment research. Equity research, broker reports, and media content available to private and non-institutional investors.
Hace 13 horas · RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commi...
